GSEA revealed that lower SLC30A3 expression was significantly associated with several neurodegenerative disease pathways, including Parkinson’s disease (NES = −1.8708, FDR = 0.0458), AD (NES = −1.9613, FDR = 0.0702), Huntington’s disease (NES = −1.8832, FDR = 0.0938), and amyotrophic lateral sclerosis (ALS) (NES = −1.7313, FDR = 0.0623). Here, SLC30A3 is linked to juvenile Huntington disease.